SCHEMBL14058540

SCHEMBL14058540

C=CC(=O)NC1C(C)CN(S(=O)(=O)c2ccc(NC(=O)c3cc4ccccc4o3)cc2)CC1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 10/20 0.52
▸ RAB9A P51151 10/20 0.52
▸ LMNA P02545 2/20 0.52
▸ CLK1 P49759 1/20 0.52
▸ KMT2A Q03164 6/20 0.50
▸ MEN1 O00255 4/20 0.50
▸ MAPT P10636 4/20 0.49
▸ MMP13 P45452 3/20 0.47
▸ MMP2 P08253 2/20 0.47
▸ TGM2 P21980 1/20 0.47
▸ ADAMTS4 O75173 1/20 0.47
▸ MMP7 P09237 1/20 0.47
▸ MMP12 P39900 1/20 0.47
▸ MMP14 P50281 1/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ TP53 P04637 2/20 0.47
▸ PKM P14618 1/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ NFKB2 Q00653 1/20 0.47
▸ RELA Q04206 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14055981 0.92 NPC1 (0.52) NPC1RAB9ALMNACLK1KMT2A
SCHEMBL14055211 0.89 TGM2 (0.59) NPC1RAB9ALMNACLK1KMT2A
SCHEMBL14054955 0.88 NPC1 (0.49) NPC1RAB9ALMNACLK1KMT2A
SCHEMBL14055435 0.87 TGM2 (0.52) NPC1RAB9ALMNACLK1KMT2A
SCHEMBL14057153 0.84 TGM2 (0.60) NPC1RAB9ALMNACLK1KMT2A
SCHEMBL14054152 0.84 NPC1 (0.52) NPC1RAB9ALMNACLK1KMT2A
SCHEMBL14054385 0.83 NPC1 (0.47) NPC1RAB9ALMNACLK1KMT2A
SCHEMBL14057190 0.83 TGM2 (0.55) NPC1RAB9ALMNACLK1KMT2A
SCHEMBL14057377 0.83 MEN1 (0.62) RAB9ALMNAKMT2AMEN1MAPT
SCHEMBL14058170 0.83 TGM2 (0.49) LMNAKMT2AMEN1MAPTTGM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889716-B2 Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof CHDI FOUNDATION, INC. (US) 2014-11-18 — — US disclosed
US-20120302539-A1 TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. 2012-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302539-A1 TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF HTT, TGM2, GRN NPC1 2123/4885RAB9A 1665/4885LMNA 4158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback